Benzinga | Jul 29, 2021 07:46AM EDT

Blueprint Medicines Q2 EPS $(1.86), Inline, Sales $27.30M Beat $19.01M Estimate

Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.86) per share which met the analyst consensus estimate. This is a 18.42 percent increase over losses of $(2.28) per share from the same period last year. The company reported quarterly sales of $27.30 million which beat the analyst consensus estimate of $19.01 million by 43.58 percent. This is a 227.16 percent increase over sales of $8.34 million the same period last year.